Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 5/20 | 0.37 |
| ▸ | PTGIR | P43119 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL493378 | 0.97 | KMT2A (0.43) | HTTHPGDNPC1KMT2AMEN1 | |
| SCHEMBL493376 | 0.96 | ALDH1A1 (0.38) | HTTHPGDNPC1KMT2AMEN1 | |
| SCHEMBL492871 | 0.96 | ALDH1A1 (0.38) | HTTHPGDNPC1KMT2AMEN1 | |
| SCHEMBL492544 | 0.96 | PTGIR (0.41) | HTTHPGDNPC1KMT2AMEN1 | |
| SCHEMBL493379 | 0.95 | KMT2A (0.44) | HTTHPGDNPC1KMT2AALDH1A1 | |
| SCHEMBL493086 | 0.93 | BDKRB1 (0.42) | HTTHPGDNPC1KMT2ASMN1; SMN2 | |
| SCHEMBL493251 | 0.92 | HTR6 (0.38) | HTTHPGDNPC1KMT2AMEN1 | |
| SCHEMBL493345 | 0.91 | KMT2A (0.39) | HTTHPGDNPC1KMT2AMEN1 | |
| SCHEMBL493179 | 0.91 | CYP3A4 (0.44) | HTTHPGDNPC1KMT2AMEN1 | |
| SCHEMBL493519 | 0.91 | LMNA (0.40) | HTTKMT2AMEN1SMN1; SMN2PTGIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | claimed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | claimed |
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| EP-2139851-A2 | SUBSTITUTED AMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-01-06 | — | — | EP | disclosed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| WO-2008131946-A2 | SUBSTITUTED AMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306084-A1 | Substituted Amide Compounds | OPRK1, NAA50, ACMSD | HTT 3541/4885HPGD 213/4885NPC1 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.